stockrowProtara Therapeutics, Inc.
TARA- EPS
- −2.86%
- Free cash flow
- −28.1%
Quarter to June 2026, against a year earlier
Follow TARA
Alert me
Protara Therapeutics, Inc. (TARA) Return on invested capital
Protara Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −255.1%, down 156.3 percentage points from fiscal 2025 (−98.7%). Over the past ten years it has ranged from −994.5% (fiscal 2023) to 0.00% (fiscal 2024); the current reading is higher than 17% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −98.7% | (98.74) |
| FY2024 | 0.00% | 994.46 |
| FY2023 | −994.5% | (757.83) |
| FY2022 | −236.6% | (236.63) |
| FY2022 | 0.00% | 41.99 |
| FY2021 | −42.0% | (41.99) |
| FY2021 | 0.00% | 70.36 |
| FY2020 | −70.4% | (70.36) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| MSLE Satellos Bioscience Inc. compare | 0.00% |
| PDSB PDS Biotechnology Corporation compare | 0.00% |
| CUE Cue Biopharma, Inc. compare | 0.00% |
| MENS Jyong Biotech Ltd. compare | 0.00% |
| YARW Yarrow Bioscience, Inc compare | 0.00% |
| MOLN Molecular Partners AG Sponsored ADR compare | 0.00% |
| SPRB Spruce Biosciences, Inc. compare | 0.00% |
| CMPX Compass Therapeutics, Inc. compare | 0.00% |
| TARA Protara Therapeutics, Inc. | −255.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)